Format

Send to

Choose Destination
Cold Spring Harb Perspect Med. 2019 Dec 2;9(12). pii: a034868. doi: 10.1101/cshperspect.a034868.

Modeling Leukemia with Human Induced Pluripotent Stem Cells.

Author information

1
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA eirini.papapetrou@mssm.edu.
2
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
3
Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
4
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.

Abstract

The reprogramming of human somatic cells into induced pluripotent stem cells (iPSCs) a little over a decade ago raised exciting prospects to transform the study and potentially also the therapy of human diseases. iPSC models have now been created for a multitude of hematologic diseases, including malignancies. Here we discuss practical aspects of iPSC modeling of malignant diseases, review recent studies, and discuss the new opportunities that iPSC models offer, as well as their current limitations and prospects for future development.

PMID:
31451537
PMCID:
PMC6886454
[Available on 2020-12-02]
DOI:
10.1101/cshperspect.a034868

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center